



RESEARCH

Open Access

# Gene polymorphism of interleukin 1 and 8 in chronic gastritis patients infected with *Helicobacter pylori*

Agostinho Caleman Neto<sup>1</sup>, Lucas T Rasmussen<sup>2</sup>, Roger W de Labio<sup>1</sup>, Valdeir F de Queiroz<sup>3</sup>, Marília de AC Smith<sup>4</sup>, Gustavo A Viani<sup>5</sup> and Spencer LM Payão<sup>1,2,6\*</sup>

## Abstract

**Background:** Epidemiological investigations have indicated that *Helicobacter pylori* induces inflammation in the gastric mucosa regulated by several interleukins. The genes *IL1B* and *IL8* are suggested as key factors in determining the risk of gastritis. The aim of this paper was to evaluate the association of gene polymorphism of interleukin-1 and interleukin-8 with chronic gastritis in *H. pylori* infected patients. A total of 60 patients underwent endoscopic procedure. Biopsy samples were collected for urease test, histopathological and molecular exams. The DNA of these samples was extracted for detection of *H. pylori* and analysis of the genes mentioned above. Patients with gastritis had a higher frequency of *H. pylori*-positive samples.

**Results:** *H. pylori* was detected in 30/60 patients (50%) by PCR. As for polymorphism of interleukin 8 (-251) gene we observed a statistical difference when analyzed TA ( $p = 0.039$ ) and TT ( $p = 0.047$ ) genotypes. In the *IL1B31* there was a statistical difference in TT ( $p = 0.01$ ) genotype and in the *IL1B-511* there wasn't any statistical difference.

**Conclusion:** Our results suggest a strong correlation between the presence of chronic gastritis and infection by *H. pylori* and that *IL1B-31TT* and *IL8-251TT* genotypes appear to act as protective factors against *H. pylori* infection while *IL8-251TA* genotype may comprise a risk factor for infection with this bacterium.

**Keywords:** *Helicobacter pylori*, Polymorphism, Interleukin

## Background

*Helicobacter pylori* is a gram-negative bacterium that colonizes the gastric antrum and/or the body of the human stomach, causing complications such as gastritis, gastric and duodenal ulcer and gastric malignancies [1,2]. *H. pylori* is present in approximately half of the world population [3]. Numerous studies have shown a significant relationship between the bacteria and the risk of gastritis [4,5]. Atherton [6] reported that the development of gastric diseases is influenced by the degree of virulence of the *H. pylori* strain, the host genetic susceptibility and environmental cofactors.

Some virulence factors, such as *vacA* and *cagA* genes, were studied since they could play an important role in

the pathogenesis of infection with *H. pylori*. The *vacA* gene, present in all strains, covers two different regions, the "s" region (s1 and s2) and the "m" region (m1 and m2) [7]. Another relevant marker of pathogenicity is the *cagA* gene, present in about 60-70% of the *H. pylori* strains. Infection with *H. pylori cagA* + strains have been associated with a greater degree of inflammation of the gastric mucosa and severe atrophic gastritis. Therefore, it has been suggested to play an important role in the development of gastric carcinoma [7,8].

Chronic infection with *H. pylori* results in inflammation of the gastric mucosa, which induces the expression of proinflammatory cytokines such as interleukins, tumor necrosis factor (alpha), and interferon [9].

Several genetic polymorphisms related to inflammatory cytotoxins have been studied and associated with an increase in the synthesis of these interleukins. The polymorphisms of some interleukins are important in cancer

\* Correspondence: slmpayao@famema.br

<sup>1</sup>Department of Genetics, FAMEMA Blood Center, Marília Medical School (FAMEMA), Marília, São Paulo State, Brazil

<sup>2</sup>Sacred Heart University (USC), Bauru, São Paulo State, Brazil

Full list of author information is available at the end of the article

susceptibility [10,11]. *H. pylori* may indirectly stimulate the activation of an inflammatory cascade of cytotoxins, which induces the production of chemokines for neutrophils and mononuclear cells, as well as interleukins IL8 and IL1, leading to a response with an inflammatory infiltrate and development of chronic gastritis [12]. The *IL8* gene has been described as having a polymorphism of an A/T base pair in the promoting region (-251) which is associated with an increase in the synthesis of interleukin by gastric epithelial cells [13,14].

The presence of -31CC or -511TT genotypes of interleukin 1B may render patients at increased risk of developing gastric atrophy and hypochlorhydria by infection of *H. pylori*, which can also lead to a two- to threefold increased risk of malignancy compared to the presence of less inflammatory genotypes [15,16]. Cytokine *IL1B-31CC/-511TT* gene polymorphisms have been shown to be related to gastric cancer and chronic gastritis development in patients infected by *H. pylori*. [16,17]. Therefore, the aim of this paper was to evaluate association of gene polymorphisms of interleukin 1 and 8 with chronic gastritis in *H. pylori* infected patients.

## Methods

### Patients and samples

Thirty adults (mean age 49.5 years old) that tested positive for *H. pylori* infection and had recurrent abdominal pain were included in the present study. Control group comprised 30 individuals in the same age group. All subjects were recruited from the Endoscopy Unit of Marília Medical School, SP, Brazil. Demographics of these patients were obtained from medical records. Three biopsy samples from each patient were collected from the gastric antrum in order to be submitted for histopathological examination, rapid urease test and DNA extraction.

All patients or legal guardians were informed about the objectives and the research protocol of the present study. They all signed an informed consent form approved by the Research Ethics Committee of Marília Medical School (protocol n. 1119/11).

### DNA extraction and *H. pylori* detection

DNA was extracted from the gastric biopsies using the QIAamp® tissue kit (Qiagen, Germany) according to the manufacturer's instructions. For the detection of *H. pylori* the PCR technique was employed, which amplifies a fragment of 150 bp from the 16S rRNA of *H. pylori* [18]. PCR conditions comprised 40 cycles of amplification, each cycle consisted of 45 seconds of denaturation at 94°C, 45 seconds of annealing at 59°C and 45 seconds extension at 72°C. In each experiment, positive (strain 26695) and negative (water) controls were included.

### Histopathology and rapid urease test

The fragments were fixed with 10% formalin and stained by hematoxylin-eosin and Giemsa. Microscopic examination defined the degree of involvement of the gastric mucosa and presence of *Helicobacter pylori*.

An antral biopsy from each patient was incubated in pre-made broth (TUPF; Laborclin, Brazil) for the urease test immediately after collection. The test was considered positive when the color of the solution changed from yellow to orange, pink, or purple within four hours of incubation at 25°C.

### Interleukin-1β genotyping

In order to characterize *IL1β* (-31,-511) gene polymorphism, restriction fragment length polymorphism (RFLP) was employed. Similarly, polymorphism of the promoting region (-511) in the *IL1β* gene was identified using PCR primers under the conditions described by Wilkinson et al. [19]. *AvaI* enzyme was used to digest the PCR products at 37°C overnight. Electrophoresis in 3% agarose gel stained with ethidium bromide showed the following bands: CC (80 and 109 bp), CT (80, 109 and 189 bp) and TT (189 bp).

To the promoting region (-31) of the *IL1β* gene the *AluI* enzyme was used for digestion at 37°C overnight [15]. The following bands, separated by electrophoresis in 3% agarose gel stained with ethidium bromide, were observed: CC (240 bp); CT (98, 137 and 240 bp) and TT (98 and 137 bp) [20].

### Interleukin-8 genotyping

*IL8* (-251) gene polymorphisms were characterized through RFLP as previously described [21]. The PCR product, a 349-bp fragment, was digested by *MunI* restriction enzyme (MBI Fermentas, Canada) overnight at 37°C and then separated by electrophoresis in 3% agarose gel stained with ethidium bromide. The digestion fragments had 349 bp with TT genotype, 202 and 147 bp with AA genotype and 349, 202 and 147 bp with TA genotype.

## Results

*Helicobacter pylori* was detected in 30 of the 60 patients (50%) by PCR whereas the urease test detected the bacterium in 21 patients (35%) (Table 1). All the samples in which the histology and urease test demonstrated the presence of *H. pylori* were also positive by PCR, showing a sensitivity of 65% and specificity of 100% by PCR and sensitivity of 43.5% and specificity of 92.9% by rapid urease test. The histopathological analysis revealed the presence of chronic gastritis in 46 subjects (76.6%).

In relation to the distribution of *IL1B-511* polymorphisms, no significant difference was observed in genotype distribution among patients infected with *H. pylori*

**Table 1 PCR and urease test detection for *H. pylori* in patients with chronic gastritis and negative control group**

PCR	Chronic gastritis		Total
	Negative (%)	Positive (%)	
Positive	0 (0)	30 (100)*	30
Negative	14 (46.7)	16 (53.3)	30
Urease	Negative	Positive	Total
Positive	1 (4.8)	20 (95.2)*	21
Negative	13 (33.3)	26 (66.7)	39

\*Statistical difference was observed.

and the control group. However, when polymorphism distribution of genotype *IL1B-31* was analyzed, a significant difference was found. Frequency of TT genotype was lower in *H. pylori*-infected patients (6.7%) when compared with the non-infected group (33.3%,  $p = 0.01$ ).

When *IL8-251* polymorphisms were analyzed, a significant variation was found. The distribution of TA genotype was higher in *H. pylori*-infected patients (63.3%) than in the control group (36.7%,  $p = 0.039$ ) whereas the frequency of TT genotype was higher in controls (43.3%) than in infected patients (20%,  $p = 0.047$ ). These results of polymorphisms are displayed in Table 2.

## Discussion

In the present study, we analyzed gene polymorphisms of *IL8* and *IL1B* together with *H. pylori* infection in groups of adult patients from Marília, SP, Brazil. Recently, researchers have been focusing their attention on the possible connection between human gene polymorphisms and *H. pylori* infection. From the investigated genes, it is important to emphasize the role of proinflammatory IL-1 polymorphism (*IL1B-511 T/-31C*), demonstrated in experiments conducted by El-Omar *et al.* [15].

In the Japanese population, *IL1B-511C > C* polymorphism was dominant among patients with advanced atrophic chronic gastritis, whereas *IL1B-511 T > T + T > C* polymorphism was more frequent in the Chinese population. In addition, no differences were found in the frequency of occurrence of C and T alleles in Tai and Vietnamese populations [22]. Regarding the Chinese case, interesting observations have shown that the *IL1B-511TT* genotype disclosed an association between peptic

disease and *H. pylori* [23]. Santos *et al.* [24] found that in the Brazilian population, *IL1β-511CC* and CT gene polymorphisms were associated with chronic gastritis and gastric cancer development in *H. pylori*-infected individuals. Our results of patients non-infected and infected with *H. pylori* revealed no association with *IL1B-511* polymorphisms.

The Chinese research also found that *IL1B-31CC* genotype was more frequent in carcinoma patients than in the control group in northern China (a region characterized by high incidence of gastric carcinoma), whereas in southern China (a region with low gastric carcinoma incidence) it was more frequent in controls than in cancer patients [23]. This indicates that the T allele could act as a proinflammatory allele in genotype *IL1B-31 T* and both genotypes may constitute independent gastric carcinoma risk factors. These hypotheses were corroborated by investigations carried out in Korea, which indicated the importance of *H. pylori* infection and presence of *IL1B-31 T* and *IL1B-511C* polymorphism for the increase of *IL1B* production by the gastric mucosa [25]. Our results suggest that the genotype *IL1B-31TT* emerge as a possible protector factor against *H. pylori*. Similar results were found in Turkish patients [26].

Cheng *et al.* [27] found no association of polymorphisms of *IL8-251 T > A* with increased risk of gastritis in Thai patients, as well as Fabris *et al.* [28] who did not find any significant association between *IL-8-251 T > A* polymorphism and *H. pylori* infection in Brazilian patients. However, some studies reported controversial results. Hofner *et al.* [29] described an association between IL8 (TA) genotype and risk for gastritis or duodenal ulcers in patients infected with *H. pylori*. Ohyauchi *et al.* [11] and Taguchi *et al.* [13] observed that the AA genotype confers higher risk for atrophic gastritis compared to the TT genotype in patients with *H. pylori*. These authors also associated TA and AA genotypes with augmented levels of IL8 and higher degree of neutrophil infiltration when compared with the TT genotype.

In the present study, we found a significant difference between TA and TT genotypes of *IL8* and the presence of *H. pylori*. However, such relation was not true for the AA genotype, which suggests that the presence of TA genotype may be a risk factor *H. pylori* infection whereas TT genotype may act as a protector factor against *H.*

**Table 2 Genotype distribution of single nucleotide polymorphisms of *IL1B* and *IL8* in Brazilian adult patients according to PCR results for *H. pylori* infection**

PCR	<i>IL1B-31</i>			Total	<i>IL1B-511</i>			Total	<i>IL8-251</i>			Total
	CC (%)	TC (%)	TT (%)*		CC (%)	TC (%)	TT (%)		AA (%)	TA (%)*	TT (%)*	
Pos.	10 (33.3)	18 (60)	2 (6.7)	30	11 (36.7)	13 (43.3)	6 (20)	30	5 (16.7)	19 (63.3)	6 (20)	30
Neg.	5 (16.7)	15 (50)	10 (33.3)	30	10 (33.3)	16 (53.3)	4 (13.4)	30	6 (20)	11 (36.7)	13 (43.3)	30

\*Statistical difference was observed.

*pylori*. In most of the eastern population the presence of the A allele in the promoting region (-251) of the *IL8* gene was related to an increased risk of stomach malignancy [11,13,30]. According to some studies, production of IL8 is augmented by the presence of A allele, and the quality and intensity of inflammatory responses produced by the host can be altered after exposure to *H. pylori* [13,14,30].

The discrepancy among *IL8* genotypes may be related to genetic differences in populations and sample sizes. However, the frequency of *IL-8-251 TA* genotype was found to be different among ethnic groups as reported in the single nucleotide polymorphism database ([http://www.ncbi.nlm.nih.gov/SNP/snp\\_ref.cgi?rs=4073](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4073)).

Polymorphisms of *IL8* are biologically important in the pathogenesis of gastric diseases. Therefore, further studies in different populations are required, since these polymorphisms in some demographic regions appear to be essential in the development of gastric diseases. Our results showed a significant role of polymorphisms of genes *IL1* and *IL8* in relation to the infection by *H. pylori* and the development of gastric mucosa inflammation. It is necessary to bear in mind that gene polymorphisms of other cytokines and other genetic factors may exert a synergistic action in the development of such changes related to *H. pylori*.

## Conclusion

In summary, the current results suggest a strong correlation between the presence of chronic gastritis and infection by *H. pylori*. In addition, the *IL1B-31TT* and *IL8-251 TT* genotypes seem to act as protective factors against *H. pylori* infection while *IL8-251TA* genotype may be a risk factor for infection with this bacterium. These polymorphisms are biologically important in the pathogenesis of gastric diseases and require more studies in different populations, since they appear to be an important variable in the development of gastric diseases in some individuals exposed to *H. pylori*.

## Ethics committee approval

Patients or legal guardians were informed about the objectives and the research protocol of the present study. They all signed an informed consent form approved by the Research Ethics Committee of Marília Medical School (protocol n. 1119/11).

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

All authors read and approved the final manuscript. ACN carried out the sample collection, DNA extraction and molecular analysis. RWL, LTR, GV, VFQ, MACS, SLMP and ACN participated in the study design, performed the statistical analysis and provided technical support and scientific discussions.

SLMP and ACN designed of the study, coordinated the research and helped to draft the manuscript.

## Acknowledgments

The authors would like to thank the State of São Paulo Research Foundation (FAPESP), grant n. 0915857-9) and Marília Medical School for their funding of this research.

## Author details

<sup>1</sup>Department of Genetics, FAMEMA Blood Center, Marília Medical School (FAMEMA), Marília, São Paulo State, Brazil. <sup>2</sup>Sacred Heart University (USC), Bauru, São Paulo State, Brazil. <sup>3</sup>Department of Digestive System Surgery, Marília Medical School (FAMEMA), Marília, São Paulo State, Brazil. <sup>4</sup>Department of Morphology, Federal University of São Paulo (UNIFESP), São Paulo, São Paulo State, Brazil. <sup>5</sup>Department of Radiotherapy and Oncology, Marília Medical School (FAMEMA), Marília, São Paulo State, Brazil. <sup>6</sup>Laboratório de Genética, Hemocentro, FAMEMA, Rua Lourival Freire, 240, Bairro Fragata, Marília, São Paulo CEP 17519-050, Brazil.

Received: 7 January 2014 Accepted: 2 April 2014

Published: 23 April 2014

## References

1. Marshall BJ: *Helicobacter pylori*. *Am J Gastroenterol* 1994, **89**(8):S116-S128.
2. Liu YE, Gong YH, Sun LP, Xu Q, Yuan Y: The relationship between *H. pylori* virulence genotypes and gastric diseases. *Pol J Microbiol* 2012, **61**(2):147-150.
3. Mitchell HM: The epidemiology of *Helicobacter pylori*. *Curr Top Microbiol Immunol* 1999, **241**:11-30.
4. Kignel S, de Almeida PF, André EA, Alves Mayer MP, Birman EG: Occurrence of *Helicobacter pylori* in dental plaque and saliva of dyspeptic patients. *Oral Dis* 2005, **11**(1):17-21.
5. De Vries AC, Kuipers EJ: Review article: *Helicobacter pylori* eradication for the prevention of gastric cancer. *Aliment Pharmacol Ther* 2007, **26**(Suppl 2):25-35.
6. Atherton JC: *H. pylori* virulence factors. *Br Med Bull* 1998, **54**(1):105-120.
7. Karlsson A, Ryberg A, Dehnoei MN, Borch K, Monstein HJ: Association between *cagA* and *vacA* genotypes and pathogenesis in a *Helicobacter pylori* infected population from South-eastern Sweden. *BMC Microbiol* 2012, **12**:129. doi:10.1186/1471-2180-12-129.
8. Rasmussen LT, de Labio RW, Neto AC, Silva LC, Queiroz VF, Smith MAC, Payão SLM: Detection of *Helicobacter pylori* in gastric biopsies, saliva and dental plaques of dyspeptic patients from Marília, São Paulo, Brazil: presence of *vacA* and *cagA* genes. *J Venom Anim Toxins Incl Trop Dis* 2012, **18**(2):8 [http://www.scielo.br/scielo.php?pid=S0074-02762010000300015&script=sci\_arttext]
9. Misiewicz JJ: Current insights in the pathogenesis of *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol* 1995, **7**:701-703.
10. Crabtree JE, Lindley IJ: Mucosal interleukin-8 and *Helicobacter pylori*-associated gastroduodenal disease. *Eur J Gastroenterol Hepatol* 1994, **6**(Suppl 1):S33-S38.
11. Ohyauchi M, Imatani A, Yonechi M, Asano N, Miura A, Iijima K, Koike T, Sekine H, Ohara S, Shimosegawa T: The polymorphism interleukin 8-251 A/T influences the susceptibility of *Helicobacter pylori* related gastric diseases in the Japanese population. *Gut* 2005, **54**(3):330-335. doi:10.1136/gut.2003.033050.
12. Israel DA, Salama N, Krishna U, Rieger UM, Atherton JC, Falkow S, Peek RM Jr: *Helicobacter pylori* genetic diversity within the gastric niche of a single human host. *Proc Natl Acad Sci U S A* 2001, **98**(25):14625-14630.
13. Taguchi A, Ohmiya N, Shirai K, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H: Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. *Cancer Epidemiol Biomarkers Prev* 2005, **14**(11 Pt):2487-2493.
14. Vinagre RMD, Corvelo TCO, Arnaud VC, Leite ACK, Barile KAS, Martins LC: Determination of strains of *Helicobacter pylori* and of polymorphism in the interleukin-8 gene in patients with stomach cancer. *Arq Gastroenterol* 2011, **48**(1):46-51.
15. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 2000, **404**(6776):398-402.



16. Wang SY, Shen XY, Wu CY, Pan F, Shen YY, Sheng HH, Chen XM, Gao HJ: **Analysis of whole genomic expression profiles of *Helicobacter pylori* related chronic atrophic gastritis with IL-1B-31CC/-511TT genotypes.** *J Dig Dis* 2009, **10**(2):99–106.
17. Sicinschi LA, Lopez-Carrillo L, Camargo MC, Correa P, Sierra RA, Henry RR, Chen J, Zabaleta J, Piazzuelo MB, Schneider BG: **Gastric cancer risk in a Mexican population: role of *Helicobacter pylori* *cagA* positive infection and polymorphisms in interleukin-1 and -10 genes.** *Int J Cancer* 2006, **118**(3):649–657.
18. Scholte GH, van Doorn LJ, Quint WG, Lindeman J: **Polymerase chain reaction for the detection of *Helicobacter pylori* in formaldehyde-sublimate fixed, paraffin-embedded gastric biopsies.** *Diagn Mol Pathol* 1997, **6**(4):238–243.
19. Wilkinson RJ, Patel P, Llewelyn M, Hirsch CS, Pasvol G, Snounou G, Davidson RN, Toossi Z: **Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis.** *J Exp Med* 1999, **189**(12):1863–1874.
20. Barbosa HPM, Martins LC, dos Santos SEB, Demarchki S, Assumpção MB, Aragão CD, Corvello TCO: **Interleukin-1 and TNF-α polymorphisms and *Helicobacter pylori* in a Brazilian Amazon population.** *World J Gastroenterol* 2009, **15**(12):1467–1471.
21. Hamajima N, Katsuda N, Matsuo K, Saito T, Hirose K, Inoue M, Zaki TT, Tajima K, Tominaga S: **High anti-*Helicobacter pylori* antibody seropositivity associated with the combination of IL-8-251TT and IL-10-819TT genotypes.** *Helicobacter* 2003, **8**(2):105–110.
22. Matsukura N, Yamada S, Kato S, Tomtitchong P, Tajiri T, Miiki M, Matsuhisa T, Yamada N: **Genetic differences in interleukin-1 betap polymorphisms among four Asian populations: an analysis of the Asian paradox between *H. pylori* infection and gastric cancer incidence.** *J Exp Clin Cancer Res* 2003, **22**(1):47–55.
23. Zeng ZR, Hu PJ, Hu S, Pang RP, Chen MH, Ng M, Sung JJ: **Association of interleukin 1B gene polymorphism and gastric cancers in high and low prevalence regions in China.** *Gut* 2003, **52**(12):1684–1689.
24. Santos JC, Ladeira MSP, Pedrazzoli J Jr, Ribeiro ML: **Relationship of IL-1 and TNF-α polymorphisms with *Helicobacter pylori* in gastric diseases in a Brazilian population.** *Braz J Med Biol Res* 2012, **45**(9):811–817.
25. Chang YW, Jang JY, Kim NH, Lee JW, Lee HJ, Jung WW, Dong SH, Kim HJ, Kim BH, Lee JI, Chang R: **Interleukin-1B (IL-1B) polymorphisms and gastric mucosal levels of IL-1beta cytokine in Korean patients with gastric cancer.** *Int J Cancer* 2005, **114**(3):465–471.
26. Erzin Y, Koksai V, Altun S, Dobrucali A, Aslan M, Erdamar S, Goksel S, Dirican A, Kocazeybek B: **Role of host interleukin 1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in clinical outcomes in *Helicobacter pylori*-positive Turkish patients with dyspepsia.** *J Gastroenterol* 2008, **43**(9):705–710.
27. Cheng HH, Chang CS, Wang HJ, Wang WC: **Interleukin-1beta and -10 polymorphisms influence erosive reflux esophagitis and gastritis in Taiwanese patients.** *J Gastroenterol Hepatol* 2010, **25**(8):1443–1451.
28. Fabris RC, Rasmussen LT, Neto AC, de Labio RW, Orcini W, Ximenez JPB, Franzolin S, Payao SLM: **Polimorfismo da Interleucina-8-251 T > A e *Helicobacter pylori*.** *Arq Catar Med* 2012, **40**(3):25–29.
29. Hofner P, Gyulai Z, Kiss ZF, Tiszai A, Tiszlavicz L, Tóth G, Szőke D, Molnár B, Lonovics J, Tulassay Z, Mándi Y: **Genetic polymorphisms of NOD1 and IL-8, but not polymorphisms of TLR4 genes, are associated with *Helicobacter pylori*-induced duodenal ulcer and gastritis.** *Helicobacter* 2007, **12**(2):124–131.
30. Ye BD, Kim SG, Park JH, Kim JS, Jung HC, Song IS: **The interleukin-8-251 A allele is associated with increased risk of noncardia gastric adenocarcinoma in *Helicobacter pylori*-infected Koreans.** *J Clin Gastroenterol* 2009, **43**(3):233–239.

doi:10.1186/1678-9199-20-17

Cite this article as: Caleman Neto *et al.*: Gene polymorphism of interleukin 1 and 8 in chronic gastritis patients infected with *Helicobacter pylori*. *Journal of Venomous Animals and Toxins including Tropical Diseases* 2014 **20**:17.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

